Abraham Fisher

AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat

The behavioral and biochemical effects of AF64A, a presynaptic cholinergic neurotoxin, were investigated. Bilateral administration of this compound into the lateral cerebral ventricles produced transient and dose-related effects on sensorimotor function and long-term impairments of cognitive behavior. Male Fischer-F344 rats dosed with either 15 or 30 nmol of AF64A reacted 29-62% faster than CSF-injected controls in a hot-plate test 14 (but not 1, 7, 21 or 28) days following dosing. The group administered 15 nmol of AF64A was also significantly more active (41%) than controls 28 days following dosing. The activity level of this group was comparable to that of controls at other times and hyperactivity was never observed in the 30 nmol group. Retention of a step-through passive avoidance task, assessed 35 days after dosing, was impaired in both the 15 and the 30 nmol groups. Their step-through latencies were significantly shorter than the control latencies, and they exhibited more partial entries during the 24-h retention test. Radial-arm maze performance, measured 60-80 days following treatment, was markedly impaired in the treated groups. Animals treated with AF64A made fewer correct responses in their first 8 choices, required more total selections to complete the task, and had an altered pattern of spatial responding in the maze. The neurochemical changes produced by AF64A, determined 120 days after dosing, were specific to the cholinergic system and consisted of decreases of ACh in both the hippocampus (15 and 30 nmol groups) and the frontal cortex (30 nmol group). The concentrations of catecholamines, indoleamines, their metabolites and choline in various brain regions were not affected by AF64A. Furthermore, histological analysis revealed that the doses of AF64A used in the present study did not damage the hippocampus, the fimbria-fornix, the septum or the caudate nucleus. These data support the contention that cholinergic processes in the hippocampus and/or frontal cortex play an important role in learning and memory processes. Furthermore, based upon the behavioral and biochemical data presented, it is suggested that AF64A could be a useful pharmacological tool for examining the neurobiological substrates of putative cholinergic disorders such as senile dementia of the Alzheimers type.

Progress in Alzheimer's and Parkinson's diseases

Pathology in Alzheimers Disease: General: 1. The Pathogenesis of Alzheimers Disease R.D. Terry. 2. Molecular and Cellular Abnormalities of Tau in Early Alzheimers Disease P. Davis, et al. Apoliprotein E: 3. ApoE and Memory in Alzheimers Disease H.S. Soininen, P.J. Riekkinen, Sr. 4. Divergent Metabolism of Apolipoproteins E3 and E4 by Cells R.E. Pitas, et al. 5. APP, ApoE, and Presenilin Transgenics: Toward a Genetic Model of Alzheimers Disease L. Pradier, et al. Apoptosis Oxidative Stress Amyloids, Inflammation and Other Defects: 8. Apoptosis in Alzheimers Disease: Inductive Agents and Antioxidant Protective Factors C.W. Cotman, C.J. Pike. 9. Membrane Constituencies and Receptor Subtype Contribute to Age-Related Increases in Vulnerability to Oxidative Stress: Implications for Neurodegenerative Disease J.A. Joseph, et al. 10. Mitochondrial Dysfunction and Alzheimers Disease S.S. Ghosh, et al. 11. Mitochondrial Dysfunction in Parkinsons Disease: Potential Applications for Cybrid Modeling of the Disease R.H. Swerdlow, et al. Amyloid Aggregation: 27. Amyloid-beta Hypothesis of Alzheimers Disease M.S. Shearman. 28. Discovery and Characterization of Peptidoorganic Inhibitors of Amyloid beta-Peptide Polymerization M.A. Findeis, S.M. Molineaux. 29. Anthracyclines and Amyloidosis C. Post, et al. 30. The Amino Terminus of the beta-Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility B. Solomon, et al. 31. Animal Models of Amyloid Aggregation and Deposition R. Kisilevsky Tau in Alzheimers Disease: 32. The Conformations of Tau Protein and Its Aggregation into Alzheimers Paired Helical Filaments E. Mandelkow, et al. Alzheimers Disease/Parkinsonss Disease and Related Disorders: Clinical and Etiological Aspects: 37. Different Cognitive Profiles on Memory Tests in Parkinsons Disease and Alzheimers Disease R.F. Allegri, et al. Parkinsons Disease--Etiology, Genetics, Treatment: 56. Genetic Aspects of Parkinsons Disease Y. Mizuno, et al. Cholinergic Strategies in Alzheimers and Parkinsons Disease: 64. The Rationale for Development of Cholinergic Therapies in AD A. Enz, P.T. Francis. Alzheimers Disease--Muscarinic Treatment and Therapy--beta-Amyloids: 70. APP Localization and Trafficking in the Central Nervouse System J.D. Buxbaum, et al. Cholinesterase Inhibitors for Treatment of Alzheimers Disease: 75. Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural Cholinesterase Inhibitors Fasciculin and Huperzine A I. Silman, et al. Neurotrophic Factor Therapy--Neuroprotection, Neurotransplantation and Other Treatment Strategies: 86. Functional Effects of GDNF on Dopamine Neurons in Animal Models of Parkinsons Disease A.F. Hoffman, et al. Animal Models in Alzheimers and Parkinsons Diseases: 93. Age Dependence of Muscarinic Plasticity in the Rat Hippocampus J.M. Auerbach, M. Segal. Diagnostic Too

Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases

Alzheimers and Parkinsons diseases are the most frequent age-related neurodegenerative diseases, and have similarities in etiology, in clinical and pathological features, and in drug development strategies like the neurotransmitter-supplementation therapy. This second of a two-volume proceedings o

Cholinergic lesion of the striatum impairs acquisition and retention of a passive avoidance response.

Significant impairments in the acquisition and retention of a step-down passive avoidance task were found in rats with striatal lesions induced by the cholinergic neurotoxin AF64A. No significant differences between control and AF64A-injected rats were found in sensitivity to electric shock or in various measures of spontaneous locomotor activity. Striatal choline acetyltransferase (CAT) activity was significantly decreased in AF64A-treated rats compared with controls, whereas glutamic acid decarboxylase (GAD) activities were not. Furthermore, there were no significant differences between groups in activities of CAT and GAD in either the cortex or the hippocampus, results that support the specificity of the lesion to the striatum. The passive avoidance deficits found in these rats after intrastriatal injection of AF64A support a role for the striatal cholinergic system in complex behavioral processes.